http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H02311423-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_280d87031f0c5786de1808713a1b76b7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K11-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K11-00 |
| filingDate | 1990-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_136f7f5d9e1238de30a5dbf5dcca458a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_706e444e1c73f5be8c9b3343c6d30908 |
| publicationDate | 1990-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H02311423-A |
| titleOfInvention | Dolastatin 13 and its dehydrogenated material |
| abstract | PURPOSE: To obtain a medicine useful for curing or controlling a neoplastic disease by containing dolastatin 13 isolated from an integumentless mollusk from the Indian Ocean or its dehydrogenated material. n CONSTITUTION: This medicine useful for inhibiting cell growth of a patient suffered from the cell growth contains dolastatin 13 expressed by the formula in which R 1 is OH and R 2 is H or dehydrodolastatin 13 in which R 1 and R 2 are combined to be form 3 membered ring (14, 15), obtained by extracting and isolating from Dolabella auricularia as an integumentless mollusk produced in the Indian Ocean as an active component. The medicine is useful for curing a neoplastic disease such as acute myelocytic leukemia, acute lymphocytic leukemia, malignant melanoma, lung cancer, neuroblastoma or colon cancer and its administration dose is in the range of 0.1-20mg for an intravenous injection, 1-50mg for an intramuscular injection and 5-100mg for an oral administration, a nasal insufflation and an aerosolization as an active component amount per 1kg of a patient. n COPYRIGHT: (C)1990,JPO |
| priorityDate | 1989-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.